Chronic Pain Market in the 7MM is expected to grow steadily during the study period 2019-2032.

DelveInsight's Chronic Pain Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Chronic Pain market share of the individual therapies, current and forecasted Chronic Pain market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). The Chronic Pain Market is expected to grow significantly owing to the increase in diagnosed genital herpes cases per year, awareness, and anticipated launch of emerging therapies by key players such as Pfizer/Eli Lilly and Company, Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation, Allergan [acquired by ABBVie], Stayble Therapeutics, Aptinyx, Lateral Pharma, Eli Lilly and Company, Samumed, and many others.

Key highlights of the Chronic Pain market report
• Out of 24,925 respondents (52.2% female, mean age 51.5 years), 15,751 (63.7%) respondents were found to be having pain. Out of this, 2,548 (15.7%) had probable NeP based on the PainDetect, which was 10% of all respondents.
• Overall, the prevalence of chronic pain was 20.4%, and the prevalence of high-impact chronic pain was 7.4%, but women were more likely to have chronic pain (21.7%) and high-impact chronic pain (8.5%) compared with men (19.0% and 6.3%, respectively).
• Chronic Pain market companies are included like Pfizer/Eli Lilly and Company, Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation, Allergan [acquired by ABBVie], Stayble Therapeutics, Aptinyx, Lateral Pharma, Eli Lilly and Company, Samumed, and many others.
• Chronic Pain therapies are included like Vyepti (Eptinezumab-jjmr), Tarlige (Mirogabalin), Fasinumab, Lorecivivint, and many others.

Get Access to a Free Copy of Our Latest Sample Chronic Pain Market Research Report @ https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Pain Overview

Chronic Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. It may be due to an injury or to the brain's inability to process pain signals properly. Pain is classified as either acute or chronic. Acute pain is usually severe and short-lived (normally 3 months), and is often the result of a disease that may require ongoing treatment.

Chronic Pain Epidemiology Segmentation in the 7MM
• Total Chronic Pain Prevalent Cases
• Chronic Pain Severity-Specific Cases
• Chronic Pain Age-specific Cases
• Chronic Pain Cause-specific cases

Download the report to understand which factors driving Chronic Pain market trends @ https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Pain Market Insight Report

Pain may occur with other symptoms depending on the underlying disease, disorder, or condition. For instance, if the pain is due to arthritis, the patient may experience pain in more than one joint. Chronic pain often leads to signs (e.g lassitude, sleep disturbance, decreased appetite, loss of taste for food, weight loss, diminished, constipation), which develop gradually. Constant, unremitting pain may lead to depression and anxiety and interfere with almost all activities. Patients may become inactive, withdraw socially, and become preoccupied with physical health. Psychologic and social impairment may be severe, causing a virtual lack of function. Diagnosing chronic pain is not easy, as there are no tools to quantify pain. Diagnosis often involves a series of tests and procedures, as well as a review of symptoms and medical history. There is no way to measure pain objectively. Only the person with chronic pain can describe how much pain he or she is feeling.

Chronic Pain Treatment Market

There are several categories of medications that are used for the treatment of chronic pain. Oral medications include those that can be taken by mouth, such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, opioid-like agents, or combinations of opioids and non-narcotic analgesics, corticosteroids, antirheumatics/immunological agents, and anticonvulsants. The most common sources of chronic pain include low back pain, headache (migraine), neuropathic pain (Neuralgia), musculoskeletal pain (Fibromyalgia), cancer pain, post-operative pain, arthritic pain (Osteoarthritis, Rheumatoid Arthritis), and others.

Chronic pain can cause significant psychological and emotional trauma and often limits an individual's ability to function fully. It is a common complaint in older adults. A person may have more than one chronic pain condition at a time. Someone may experience chronic pain long after they are injured or without any apparent cause. In some cases, more than one factor may be involved.

Chronic Pain Companies & Pipeline Therapies
• Pfizer/Eli Lilly and Company: Vyepti (Eptinezumab-jjmr)
• Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation
• Allergan [acquired by ABBVie]: Tarlige (Mirogabalin)
• Stayble Therapeutics: Ajovy (Fremanezumab)
• Aptinyx: Fasinumab
• Lateral Pharma: Lorecivivint (SM04690), and others
• Eli Lilly and Company
• Samumed
• Sorrento Therapeutics, and others.

Chronic Pain Emerging Drugs
• Tanezumab (Pfizer/Eli Lilly and Company)
• Fasinumab/REGN475 (Regeneron Pharmaceuticals/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation)
• Atogepant (Allergan [acquired by ABBVie])
• Ampion (Ampio Pharmaceuticals)
• Rexlemestrocel/MPC-06-ID (Gruenthal/Mesoblast)

Learn more about the FDA-approved drugs for Chronic Pain Treatment @ https://www.delveinsight.com/report-store/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Pain Market Research Report
• Coverage- 7MM
• Chronic Pain market companies- Pfizer/Eli Lilly and Company, Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation, Allergan [acquired by ABBVie], Stayble Therapeutics, Aptinyx, Lateral Pharma, Eli Lilly and Company, Samumed, and many others.
• Chronic Pain Pipeline Therapies- Vyepti (Eptinezumab-jjmr), Tarlige (Mirogabalin), Fasinumab, Lorecivivint, and many others.
• Unmet Needs, KOL's views, Analyst's views, Chronic Pain Market Access and Reimbursement

Table of content
1. Key Insights
2. Chronic Pain Report Introduction
3. Chronic Pain Market Overview at a Glance
4. Chronic Pain Executive Summary
5. Chronic Pain Epidemiology and Market Methodology
6. Chronic Pain Disease Background and Overview
7. Chronic Pain Diagnosis of Chronic Pain
8. Current Chronic Pain Treatment
9. Chronic Pain Epidemiology and Patient Population
10. The United States
11. EU-5
12. Japan
13. Patient Journey
14. Key Endpoints in Chronic Pain Clinical Trials
15. Chronic Pain Marketed Therapies
16. Chronic Pain Emerging Therapies
17. 7 Major Market Analysis
18. The United States Market Size
19. EU-5 Chronic Pain Market Size
20. Japan
21. Chronic Pain Market Access and Reimbursement
22. Chronic Pain Market Drivers
23. Chronic Pain Market Barriers
24. SWOT Analysis
25. Unmet Needs
26. Appendix
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight

Connect with our Business Consultant @ https://www.delveinsight.com/report-store/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +919650213330
Address: 304 S. Jones Blvd #2432 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.